Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV000049458 | SCV001368409 | likely pathogenic | Glycine encephalopathy | 2019-02-28 | criteria provided, single submitter | clinical testing | This variant was classified as: Likely pathogenic. The following ACMG criteria were applied in classifying this variant: PM3,PM2,PS1,PP3. |
Ambry Genetics | RCV004018964 | SCV004876279 | uncertain significance | Inborn genetic diseases | 2023-10-10 | criteria provided, single submitter | clinical testing | The c.176G>C (p.R59T) alteration is located in exon 1 (coding exon 1) of the GLDC gene. This alteration results from a G to C substitution at nucleotide position 176, causing the arginine (R) at amino acid position 59 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049458 | SCV000081892 | probable-pathogenic | Glycine encephalopathy | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |